Industry News

Johnson & Johnson has reported encouraging Phase 3 results for a combination therapy featuring TALVEY (talquetamab-tgvs) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), highlighting the growing potential of bispecific antibody-based treatment strategies in earlier-line relapsed or refractory multiple myeloma (RRMM).

Johnson & Johnson has announced encouraging results from its pivotal Phase 2/3 ENERGY study evaluating IMAAVY (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune blood disorder that currently has no FDA-approved therapies. The findings suggest that the investigational treatment could offer a much-needed targeted option for patients struggling with chronic anemia and severe fatigue.

India is aiming to achieve pharmaceutical exports worth USD 50 billion by 2030, driven by a strong focus on quality manufacturing, innovation, regulatory excellence, and international collaboration. The vision was highlighted during discussions involving global drug regulators, industry leaders, and policymakers, underscoring India's ambition to strengthen its position as a leading supplier of medicines to the world.

In a major advancement for HIV treatment, Gilead Sciences and Merck have announced positive topline results from two pivotal Phase 3 clinical trials evaluating an investigational once-weekly oral HIV therapy that combines islatravir and lenacapavir. The promising findings bring the healthcare industry one step closer to introducing what could become the world's first long-acting oral HIV treatment taken just once a week.

Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.

Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.